to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
250
24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale(FWS)
The Investigator assessed the severity of the patient's Crow's Feet lines at maximum smile using the 4-point Facial Wrinkle Scale where 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.